See more : CONSOL Energy Inc. (CEIX) Income Statement Analysis – Financial Results
Complete financial analysis of BeiGene, Ltd. (BGNE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BeiGene, Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- Orexo AB (publ) (ORXOF) Income Statement Analysis – Financial Results
- RDC Semiconductor Co., Ltd. (3228.TWO) Income Statement Analysis – Financial Results
- AdTheorent Holding Company, Inc. (ADTH) Income Statement Analysis – Financial Results
- Dynamic Design Co., LTD. (145210.KS) Income Statement Analysis – Financial Results
- Vicat S.A. (SDCVF) Income Statement Analysis – Financial Results
BeiGene, Ltd. (BGNE)
About BeiGene, Ltd.
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat lymphomas; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Lifirafenib and BGB-3245 to treat melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. The company has strategic collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, and Bristol Myers Squibb company. BeiGene, Ltd. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.46B | 1.42B | 1.18B | 308.87M | 428.21M | 198.22M | 238.39M | 1.07M | 8.82M | 13.04M | 11.15M |
| Cost of Revenue | 379.92M | 1.93B | 1.62B | 1.37B | 998.53M | 707.71M | 273.99M | 98.03M | 58.25M | 21.86M | 13.46M |
| Gross Profit | 2.08B | -511.06M | -447.86M | -1.06B | -570.32M | -509.49M | -35.61M | -96.96M | -49.43M | -8.83M | -2.32M |
| Gross Profit Ratio | 84.55% | -36.09% | -38.07% | -342.10% | -133.19% | -257.03% | -14.94% | -9,061.96% | -560.73% | -67.72% | -20.77% |
| Research & Development | 1.78B | 1.64B | 1.46B | 1.29B | 927.34M | 679.01M | 269.02M | 98.03M | 58.25B | 21.86M | 13.46M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 195.39M | 62.60M | 20.10M | 7.31M | 6.93M | 3.14M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.50B | 1.28B | 990.12M | 600.18M | 388.25M | 195.39M | 62.60M | 20.10M | 7.31M | 6.93M | 3.14M |
| Other Expenses | 3.50M | -1.64B | 750.00K | 846.00K | 1.33M | 894.00K | 250.00K | -2.49M | -916.00K | 600.00K | 584.00K |
| Operating Expenses | 3.29B | 1.28B | 990.87M | 601.02M | 389.58M | 196.28M | 62.85M | 20.10M | 7.31M | 6.93M | 3.14M |
| Cost & Expenses | 3.67B | 3.21B | 2.62B | 1.97B | 1.39B | 903.99M | 336.84M | 118.13M | 65.56M | 28.79M | 16.61M |
| Interest Income | 0.00 | 74.18M | 13.51M | 2.00M | 9.13M | 0.00 | 0.00 | 0.00 | 1.79M | 40.00K | 2.00K |
| Interest Expense | 0.00 | 52.48M | 0.00 | 338.00K | 9.13M | 13.95M | 0.00 | 383.00K | 1.23M | 3.55M | 3.16M |
| Depreciation & Amortization | 87.68M | 66.28M | 46.46M | 31.79M | 18.62M | 9.89M | 4.59M | 1.91M | 1.55M | 1.56M | 1.59M |
| EBITDA | -1.12B | -1.73B | -1.39B | -1.63B | -941.27M | -695.38M | -93.70M | -115.15M | -55.20M | -14.20M | -3.15M |
| EBITDA Ratio | -45.74% | -126.34% | -122.25% | -536.41% | -223.85% | -342.64% | -36.12% | -10,958.32% | -616.24% | -101.03% | -24.64% |
| Operating Income | -1.21B | -1.79B | -1.44B | -1.66B | -959.89M | -705.77M | -98.46M | -117.06M | -56.75M | -15.76M | -5.46M |
| Operating Income Ratio | -49.12% | -126.40% | -122.31% | -536.69% | -224.16% | -356.05% | -41.30% | -10,940.19% | -643.66% | -120.88% | -48.96% |
| Total Other Income/Expenses | 381.90M | -171.37M | 147.00K | 39.49M | 16.31M | 15.94M | 7.39M | -2.10M | -357.00K | -2.79M | -2.44M |
| Income Before Tax | -825.84M | -1.96B | -1.44B | -1.62B | -943.59M | -689.83M | -91.06M | -119.16M | -57.10M | -18.55M | -7.89M |
| Income Before Tax Ratio | -33.59% | -138.50% | -122.30% | -523.90% | -220.35% | -348.01% | -38.20% | -11,136.73% | -647.71% | -142.28% | -70.81% |
| Income Tax Expense | 55.87M | 42.78M | -25.23M | -17.67M | 6.99M | -15.80M | 2.24M | 54.00K | 872.00K | 763.00K | 719.00K |
| Net Income | -881.71M | -2.00B | -1.41B | -1.60B | -950.58M | -673.77M | -93.11M | -119.22M | -57.10M | -18.28M | -7.49M |
| Net Income Ratio | -35.86% | -141.52% | -120.15% | -518.18% | -221.99% | -339.91% | -39.06% | -11,141.78% | -647.71% | -140.22% | -67.22% |
| EPS | -8.45 | -19.43 | -15.23 | -19.17 | -15.83 | -12.15 | -2.04 | -3.00 | -1.81 | -0.35 | -0.14 |
| EPS Diluted | -8.45 | -19.43 | -15.23 | -19.17 | -15.83 | -12.15 | -2.04 | -3.00 | -1.81 | -0.35 | -0.14 |
| Weighted Avg Shares Out | 104.39M | 103.13M | 92.79M | 83.47M | 60.05M | 55.44M | 45.54M | 39.68M | 31.52M | 52.66M | 52.66M |
| Weighted Avg Shares Out (Dil) | 104.39M | 103.13M | 92.79M | 83.47M | 60.05M | 55.44M | 45.54M | 39.68M | 31.52M | 52.66M | 52.66M |
BeiGene and CLL Society Partner to Advance Test Before Treat™ Campaign, Promoting Biomarker Testing to Improve Patient Outcomes in CLL
BeiGene to Host Investor Webcast Highlighting Key Data from ASH and the San Antonio Breast Cancer Symposium on December 16, 2024
BeiGene: Nearing Profitability On TEVIMBRA Approval In The EU And US
European Commission Approves BeiGene's TEVIMBRA for First-Line Treatment of Advanced/Metastatic Esophageal Squamous Cell Carcinoma and Gastric or Gastroesophageal Junction Cancer
BeiGene to Present at Upcoming Investor Conferences
Labcorp CFO Glenn Eisenberg Announces Plans to Retire
BeiGene Announces Settlement of Litigation Against Generic Filer of BRUKINSA
BeiGene Unveils Proposed Name Change to BeOne Medicines, Reaffirming Its Mission to Unite Global Community Against Cancer
BeiGene Announces Third Quarter 2024 Financial Results and Corporate Updates
BeiGene: TEVIMBRA European Push Continues With Positive CHMP Opinion
Source: https://incomestatements.info
Category: Stock Reports